The following are research articles with promising results for auto-immune conditions, cancer, COPD, and other. Please note that we are excited about the future of stem cell therapy but we DO NOT offer treatment at Neo Matrix Medical for these conditions.

Treatment of Psoriasis with Mesenchymal Stem Cells 

  • Unexpectedly, his skin lesions, as well as engraftment, recovered day by day. Six months later, the patient’s lymphoma underwent complete remission and his psoriasis was significantly relieved (Figure A.2). The skin returned to normal within 12 months (Figure A.3). Now the patient has been monitored for nearly 5 years. His condition remains stable, with no recurrence of lymphoma or psoriasis.

Neural differentiation and potential use of stem cells from the human umbilical cord for central nervous system transplantation therapy. 

  •  Recent findings also suggest that neurons derived from cord stroma mesenchymal cells could alleviate movement disorders in hemiparkinsonian animal models. We review here the neurogenic potential of umbilical cord stem cells and discuss possibilities of their exploitation as an alternative to human embryonic stem cells or neural stem cells for transplantation therapy of traumatic CNS injury and neurodegenerative diseases.

Discarded Wharton’s Jelly of the Human Umbilical Cord: A Viable Source for Mesenchymal Stem Cells

  • WJ-MCSs are still the ideal future for cell therapy; their properties of high proliferation capability and versatility to differentiate between three lineages allow them to lower immunogenicity and have the potential to treat an array of diseases and disorders
    • Diabetes… Also additional research suggests that WJ-MSC may have the potential to benefit in the direct treatment of diabetes mellitus [38]. By using markers that indicate when certain genes are expressed, models have shown that WJ-MSCs have the capability to differentiate into all sorts of pancreatic cells including the insulin-producing β cells [39]. Using immunohistochemistry and ELISA assays, a significantly greater amount of insulin and C-peptide protein was released from the differentiated cells than from the undifferentiated cells.
    • Liver disease…Transplantation of WJ-MSCs has also been tested in liver fibrosis. Using carbon tetrachloride (CCl4), rats were experimentally induced display liver fibrosis and 4 weeks later received WJ-MSCs injections [22]. After an additional 4 weeks, there was a remarkable decrease in the liver fibrosis in the rats treated with WJ-MSCs as compared to the rats that were not treated with the WJ-MSCs. Some WJ-MSCs exhibited phenotypes of the liver, and those WJ-MSCs that did not differentiate had the capability to secrete cytokines that have the potential to restore liver function [23]. These observations indicate a multi-pronged reparative mechanism of WJ-MSCs involving specific lineage differentiation and therapeutic molecules that are key pathways towards tissue repair.

Human Wharton’s Jelly-Derived Stem Cells Display Immunomodulatory Properties and Transiently Improve Rat Experimental Autoimmune Encephalomyelitis. 

  • Collectively, we show that WJ-MSCs have trophic support properties and effectively modulate immune cell functioning both in vitro and in the EAE model, suggesting WJ-MSC may hold promise for MS therapy.

Role of Nonmuscle Myosin II in Migration of Wharton’s Jelly-Derived Mesenchymal Stem Cells. 

  • Role of Nonmuscle Myosin II in Migration of Wharton’s Jelly-Derived Mesenchymal Stem Cells.
  • It is the promise of regeneration and therapeutic applications that has sparked an interest in mesenchymal stem cells (MSCs). Following infusion, MSCs migrate to sites of injury or inflammation by virtue of their homing property.

Lung mesenchymal stem cells-derived extracellular vesicles attenuate the inflammatory profile of Cystic Fibrosis epithelial cells.

  • We conclude that the anti-inflammatory and anti-oxidant efficacy of EVs (extra cellular vesicles) derived from lung MSCs could be mediated by up-regulation of the PPARγ axis, whose down-stream effectors (NF-kB and HO-1) are well-known modulators of these pathways.
  • EVs could be a novel strategy to control the hyper-inflamed condition in Cystic Fibrosis.

Interaction of Wharton’s jelly derived fetal mesenchymal cells with tumor cells. 

  • Currently, pre-clinical and clinical studies have demonstrated the importance of stem cell based therapies for the treatment of human diseases. Fetal Mesenchymal Stem Cells (Fetal MSCs) are potential candidates that can be utilized for the treatment of different types of cancer. Recently, Wharton’s jelly (umbilical cord matrix) was proved to be a rich source of MSCs and they can be isolated by non-invasive methods such as Ficoll density gradient and antibodies coupled magnetic beads without any ethical issues. Documentation based on various literatures emphasized that fetal MSCs isolated from fetal umbilical cord possess beneficial activity in cancer therapy than adult MSCs. Specific markers of fetal MSCs such as tumor tropism (exhibit tumor microenvironments which act similar to anti inflammation immune cells) and low immunogenicity conferred them as a promising tool in gene therapy based oncology research. Based on these facts, this review summarizes the potential interaction of fetal mesenchymal stem cells with tumor cells and their use in clinical protocols.

Autologous Cellular Therapy and its Effects on COPD: A Pilot Study

COPD Improves with Stem Cell Therapy

Stem cell therapies for chronic obstructive pulmonary disease: current status of pre-clinical studies and clinical trials 

  • In summary, the approaches discussed for regenerative therapies have demonstrated positive effects in COPD animal models and have been safe in clinical trials. However, greater effort must be taken to develop approaches that will lead towards a curing solution to COPD patients.   ADDITIONAL RESEARCH

Stem cell therapy in chronic obstructive pulmonary disease. How far is it to the clinic? 

  • Previous studies suggest that cell-based therapies and novel bioengineering approaches may be potential therapeutic strategies for lung repair and remodelling. In this paper, we review the current evidence of stem cell therapy in COPD.

The clinical use of regenerative therapy in COPD.  

  • Animal and human studies have demonstrated that tissue-specific stem cells and bone marrow-derived cells contribute to lung tissue regeneration and protection, and thus administration of exogenous stem/progenitor cells or humoral factors responsible for the activation of endogenous stem/progenitor cells may be a potent next-generation therapy for chronic obstructive pulmonary disease.

Concise Review: Clinical Prospects for Treating Chronic Obstructive Pulmonary Disease with Regenerative Approaches 

  • Cell therapies using various stem cells have been extensively evaluated. The lung is one of the easiest organs in which to instill exogenous cells because cells can be applied through both the airway and circulation. In addition, most of the intravenously instilled cells are trapped within the pulmonary circulation; therefore, the efficacy of cell delivery is naturally high.
  • Mesenchymal stem cells (MSCs) are the most extensively evaluated candidates for clinical cell-based therapy. Many clinical trials using MSCs have been registered and are ongoing. Autologous MSCs are easily isolated from the bone marrow and other tissues. MSCs are expected to reduce inflammation and promote the repair process. These beneficial effects are thought to be based on the ability of MSCs to modulate the immune system and their capacity to produce growth factors and cytokines [49], such as keratinocyte growth factor, HGF, and prostaglandin E2.
  • Because of these anti-inflammatory effects, a phase II clinical trial using MSCs has been performed in moderate and severe COPD patients [50]. The trial successfully demonstrated the safety of cell therapies using MSCs and some reduction in the inflammatory response in COPD patients but did not show any beneficial effects on lung function. Additional studies, especially in early-stage COPD patients, are needed.

Stem cell therapy: the great promise in lung disease.

  • The use of adult stem cells to help with lung regeneration and repair could be a newer technology in clinical and regenerative medicine. In fact, different studies have shown that bone marrow progenitor cells contribute to repair and remodeling of lung in animal models of progressive pulmonary hypertension. Therefore, lung stem cell biology may provide novel approaches to therapy and could represent a great promise for the future of molecular medicine. In fact, several diseases can be slowed or even blocked by stem cell transplantation.

Current Status of Stem Cells and Regenerative Medicine in Lung Biology and Diseases

  • Exciting progress in each of these areas provides further understanding of lung biology and repair after lung injury and further a sound scientific basis for therapeutic use of cell therapies and bioengineering approaches in treatment of lung diseases

Lung Regeneration: Endogenous and Exogenous Stem Cell Mediated Therapeutic Approaches 

  • Much study, so far, has been done to evaluate MSC-mediated cell therapy in various lung conditions, albeit mostly in animal models. In this case, it is important to note that the bulk of studies suggest the infused MSCs exhibits reparative/healing effects mostly through paracrine or immunomodulatory effects on recipient lung tissue, but not by engraftment Thus, it is imperative to view MSC therapy as cell-based immunomodulatory therapy rather than as attempts to regenerate or reconstitute lung tissues [6]. Nonetheless, much effort has been taken to date to understand the molecular mechanisms of lung development, disease dynamics and its regenerative process.

Endogenous and exogenous stem cells: a role in lung repair and use in airway tissue engineering and transplantation 

  • Human amniotic fluid SCs (hAFSCs) and umbilical blood cord (UBC)-derived SCs are new cell resources for lung regeneration. Human umbilical cord blood is a promising source for human MSCs Recent advances in airway tissue engineering provide a good opportunity for the treatment of a wide range of lung defects. In addition to the respiratory failure cases mentioned above, SC-based therapies show great potential for new clinical applications against acute respiratory distress syndrome [72], asthma [73], and bronchopulmonary dysplasia [74]. At present, the therapeutic potential of SCs is intensively assessed in rodent models of these diseases, with the possibility of proceeding to clinical trials

Adult stem cells for chronic lung diseases 

  • Conclusion: As a selfrepair mechanism, living organisms have stem cells that are attracted to sites of injury. Chronic injury as well as ageing could exhaust and impair stem cell reparative capacity as well as diminish number of available stem cells. The mechanism(s) by which alterations in the homeostasis of stem cells pools are involved in the pathogenesis of chronic lung diseases is unknown. If stem cell exhaustion and ageing is the cause of morbid states, stem cellbased therapies will be able to prevent and treat them. Restoration of stem cells has shown promising therapeutic benefits for certain lung pathologies. Particularly, the immunomodulatory capacity of BMSC has been shown to be beneficial for lung diseases with exacerbated inflammatory responses. However, a generalized use of BMSC in chronic lung diseases must be considered with caution, and careful studies are still required to establish safety and efficacy of such use.

Lung regeneration using amniotic fluid mesenchymal stem cells 

  • In this review, we give an update on the use of amniotic fluid mesenchymal stem cells (AFMSCs) as an optimal source for lungs scaffold re-cellularization, due to their limitless accessibility and possibility for proliferation and differentiation. Further studies will be required in tissue engineering (TE) and regenerative medicine (RM), especially shifting our focus towards AFMSCs as a cell source for this regeneration.

Stem cell therapy for lung diseases: From fundamental aspects to clinical applications. 

  • This review summarizes the recent advances in stem cell treatments and the research efforts conducted through the application of stem cell therapy for respiratory system diseases. In particular, researchers have used animal models to gather data about treating lung injury by stem cell transplantation. This review concentrated on the findings about route, timing and adjustment of cell transplantation dose, optimum stem cell type selection and potency marker of cells as therapeutic agents.

Adult stem cells in the treatment of autoimmune diseases 

  • The past decade has seen the introduction of many agents, especially biologics, which have allowed a more successful control of AD manifestations. However, the elusive aim of tolerance induction has not yet been achieved. It could be that through harnessing the complex and multifaceted potential of cellular-based therapies, especially HSCT, a ‘resetting‘ of auto-aggressive immune reactions while maintaining protective immunity will be possible. In addition, the anti-proliferative and immunomodulatory properties of MSCs combined with their immunological privilege and seemingly low toxicity may offer a new strategy for controlling and protecting vital organs from inflammatory, destructive autoimmune reactions.

Treatment of severe autoimmune disease by stem-cell transplantation 

  • Transplantation of haematopoietic stem cells — cells capable of self renewing and reconstituting all types of blood cell — can treat numerous lethal diseases, including leukaemias and lymphomas. It may now be applicable for the treatment of severe autoimmune diseases, such as therapy-resistant rheumatoid arthritis and multiple sclerosis. Studies in animal models show that the transfer of haematopoietic stem cells can reverse autoimmunity, and several mechanistic pathways may explain this phenomenon.

A lethal autoimmune disease succumbs to stem cells 

  • The results are consistent with two previous stem-cell trials, and should help to establish stem-cell transplants as a standard treatment for individuals with severe scleroderma, according to the researchers.

Human Umbilical Cord Blood Stem Cells Infusion in Spinal Cord Injury: Engraftment and Beneficial Influence on Behavior 

  • Open-field test scores of spinal cord injured rats treated with human cord blood at 5 days were significantly improved as compared to scores of rats similarly injured but treated at day 1 as well as the otherwise untreated injured group. The results suggest that cord blood stem cells are beneficial in reversing the behavioral effects of spinal cord injury, even when infused 5 days after injury. Human cord blood-derived cells were observed in injured areas, but not in non-injured areas, of rat spinal cords, and were never seen in corresponding areas of spinal cord of non-injured animals. The results are consistent with the hypothesis that cord blood-derived stem cells migrate to and participate in the healing of neurological defects caused by traumatic assault.

Bone Marrow Mononuclear Cells Have Neurovascular Tropism and Improve Diabetic Neuropathy 

  • In this study, we showed that the transplantation of BMNCs restored the vascularity and function of diabetic nerves, supporting the hypothesis that neural vascularity is pathophysiologically associated with the development and reversal of DN

Multipotent Stem Cells from Umbilical Cord: Cord Is Richer than Blood! 

  • Despite the advantages of HSC from UCB in hematopoietic reconstitution [13, 14–15], results from the present study demonstrated that UC, and not UCB, is the best choice for isolating MSCs for future applications. Until very recently, BM has been considered the main source of MSCs. Panepucci et al. demonstrated that MSCs derived from UC and BM are highly similar at the transcriptional level, reinforcing the usefulness of UC from neonates [34].

LifeSparing Effect of Human Cord BloodMesenchymal Stem Cells in Experimental Acute Kidney Injury†

  • CONCLUSION In conclusion, in a murine model of AKI, hCBMSC treatment promotes kidney regeneration and prolongs survival better than any other cellular approach attempted so far. These effects appear to be mediated by a paracrine action of hCBMSCs on tubular cells involving lowering oxidative stress, apoptosis, and inflammation. These data indicate that hCBMSCs have to be considered as one possible future option for cellular therapy of AKI in humans.

Human Umbilical CordDerived Mesenchymal Stromal Cells Improve Left Ventricular Function, Perfusion, and Remodeling in a Porcine Model of Chronic Myocardial Ischemia 

  • Conclusion This is the first study to provide evidence that intracoronary delivery combined with multiple intravenous infusions of UCMSCs improves LV function, perfusion, and remodeling in a large animal model of chronic myocardial ischemia. In the present study, we observed neither tumor nor teratoma formation in human UCMSCtransplanted animals, and no sustained ventricular arrhythmia or anaphylaxis was observed. Because these cells can be isolated from medical waste, expanded, banked, and administered to patients at any time without immunological rejection, human UCMSCs might be an ideal cell source for cardiac cell therapy and hold promise as an offtheshelf product.

Intravenous Infusion of Umbilical Cord BloodDerived Mesenchymal Stem Cells in Rheumatoid Arthritis: A Phase Ia Clinical Trial 

  • Conclusion This is the first phase Ia study of RA patients that evaluated the safety and tolerability of a single intravenous infusion with hUCBMSCs and with cell numbers of up to 1 × 108, revealing an acceptable safety profile. Conclusions regarding efficacy in phase I trials are limited, and although evaluation of disease activity was not the primary objective of this study, a single infusion of hUCBMSCs effectively reduced the mean DAS28 at week 4. Considering favorable safety profiles, intravenous infusion of hUCBMSCs may constitute a therapeutic option for patients with RA, who are refractory to or intolerant of MTX. There is a wide array of opportunities for future clinical studies with different hUCBMSC infusion strategies in which safety profiles should be carefully monitored and outcome measures further refined for optimized effectiveness evaluations.

Therapeutic potential of allogeneic mesenchymal stromal cells transplantation for lupus nephritis. 

  • Proteinuria levels improved dramatically during the 1st month after treatment and the ameliorations were sustained throughout the follow-up period. SLEDAI scores revealed early, durable, and substantial remissions that were complete for two patients and partial for the third patient and that permitted medication doses to be reduced 50-90%. These favourable outcomes support completion of the randomized and controlled MSC trial for SLE.

Mesenchymal Stromal Cells Based Therapy in Systemic Sclerosis: Rational and Challenges 

  • The ability of MSCs to positively influence processes such as immunosuppression, angiogenesis and inflammation generated a lot of interest and enthusiasm from clinicians and researchers alike. It is apparent that many questions remain unanswered, however what is becoming clear is that MSCs-based therapy should considered as a safe and potentially efficient therapeutic option in the management of advanced stage of SSc.

The Use of Human Mesenchymal Stem Cells as Therapeutic Agents for the in vivo Treatment of Immune-Related Diseases: A Systematic Review 

  • In this systematic review, the treatment of many types of immune-related diseases was conducted through the administration of hMSCs. Positive results were usually reported and attributed to the paracrine effects of molecules secreted by hMSCs on immune cells. In conclusion, despite the need for further studies, the treatment of immune-related diseases through the administration of hMSCs is progressively ceasing being only a promising possibility and becoming a reality.

Mesenchymal stem cells alleviate experimental autoimmune cholangitis through immunosuppression and cytoprotective function mediated by galectin-9 

  • In summary, the present study shows that UC-MSCs exert profound inhibitory effects on inflammatory responses to alleviate liver injury in experimental autoimmune cholangitis mice. Furthermore, UC-MSCs inhibit Th1 and Th17 cell responses as well as aberrant chemokine activities through Gal-9–mediated immunosuppression. Additionally, the induction of Gal-9 in UC-MSCs is mediated by the STAT and JNK signaling pathways. Our results provide novel insights into the clinical application of UC-MSCs in the treatment of PBC.

The Beneficial Effect of Human Amnion Mesenchymal Cells in Inhibition of Inflammation and Induction of Neuronal Repair in EAE Mice 

  • Recently, accumulating evidence showed that MSCs from different origins, including adipose-derived, bone marrow-derived, and umbilical cord-derived, could attenuate the disease progression in EAE animal models [27–29]. Furthermore, autologous bone marrow-derived MSCs transplantation and allogeneic umbilical cord-derived MSCs transplantation for the treatment of MS have been proved safe and effective in clinical trials, which showed that treatment improved the course of the disease, reduced the inflammatory response, and promoted neuroprotection

TGF-β and mesenchymal stromal cells in regenerative medicine, autoimmunity and cancer. 

  • Multipotent mesenchymal stromal cells (MSCs) represent a promising cell-based therapy in regenerative medicine and for the treatment of inflammatory/autoimmune diseases. Importantly, MSCs have emerged as an important contributor to the tumor stroma with both pro- and anti-tumorigenic effects

Modulation of autophagy as new approach in mesenchymal stem cell-based therapy.

  • Here, we review the current literature describing mechanisms by which modulation of autophagy strengthens pro-angiogenic and immunosuppressive characteristics of MSCs in animal models of multiple sclerosis, osteoporosis, diabetic limb ischemia, myocardial infarction, acute graft-versus-host disease, kidney and liver diseases. Obtained results suggest that modulation of autophagy in MSCs may represent a new therapeutic approach that could enhance efficacy of MSCs in the treatment of ischemic and autoimmune diseases.

Therapeutic Applications of Mesenchymal Stem Cells for Systemic Lupus Erythematosus. 

  • Mesenchymal stem cells (MSCs) have been intensively studied and applied in regenerative medicine and tissue engineering. Recently, their immune modulation functions make them as attractive potential approaches for autoimmune disease treatment. Systemic lupus erythematosus (SLE) is one type of chronic autoimmune diseases with multi-organ damaged by the immune system. Although current available treatments are effective for some patients, others are refractory for these therapies. The immuno-modulatory and regenerative characteristics of MSCs make them as one promising candidate for treating SLE.

Cell therapies for refractory rheumatoid arthritis. 

  • Recently, cell-based therapies have become the focus, attracting more attention due to their potential for remission induction. Several immune-regulatory cell types, such as haematopoietic stem cells, mesenchymal stem cells and regulatory T cells have been defined as novel targets.

Mesenchymal stem cell transplantation in systemic lupus erythematous, a mesenchymal stem cell disorder. 

  • MSCs from SLE patients have demonstrated defects such as aberrant cytokine production. Moreover, impaired phenotype, growth and immunomodulatory functions of MSCs from patients with SLE in comparison to healthy controls have been reported. Therefore, it is hypothesized that SLE is potentially an MSC-mediated disease and, as a result, allogeneic rather than autologous MSC transplantation can be argued to be a potentially advantageous therapy for patients with SLE.

Hematopoietic and mesenchymal stem cell transplantation for severe and refractory systemic lupus erythematosus. 

  • Recently, growing evidence suggests that the functions of hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs) are disrupted in SLE pathology. And HSC or MSC transplantation (HSCT/MSCT) can offer an effective and safe therapy for the severe SLE patients, resulting in disease clinical remission and improvement of organ dysfunction.

The protective effects of human umbilical cord mesenchymal stem cells on damaged ovarian function: A comparative study.

  • A higher level of expression of anti-apoptotic and antioxidant enzymes was noted in the ovaries of groups treated with hUCMSCs. These parameters were enhanced more when mice were treated with hUCMSCs for 1 month than when they treated with hUCMSCs for 2 weeks. IV was better able to restore ovarian function than MI. These results suggest that both methods of transplantation may improve ovarian function and that IV transplantation of hUCMSCs can significantly improve ovarian function and structural parameters more than MI transplantation of hUCMSCs can.

Human umbilical cord mesenchymal stem cells improve the reserve function of perimenopausal ovary via a paracrine mechanism. 

  • CONCLUSIONS: Our results suggest that hUCMSCs can promote ovarian expression of HGF, VEGF, and IGF-1 through secreting those cytokines, resulting in improving ovarian reserve function and withstanding ovarian senescence.

Intramuscular injection of human umbilical cord-derived mesenchymal stem cells improves cardiac function in dilated cardiomyopathy rats 

  • BACKGROUND: Stem cells provide a promising candidate for the treatment of the fatal pediatric dilated cardiomyopathy (DCM). This study aimed to investigate the effects of intramuscular injection of human umbilical cord-derived mesenchymal stem cells (hUCMSCs) on the cardiac function of a DCM rat model.
  • CONCLUSIONS: Intramuscular injection of UCMSCs can improve DCM-induced cardiac function impairment and protect the myocardium. These effects may be mediated by regulation of relevant cytokines in serum and the myocardium.

Long term effect and safety of Wharton’s jelly-derived mesenchymal stem cells on type 2 diabetes

  • In conclusion, the findings of the present study suggested that WJ-MSC infusion may effectively ameliorate hyperglycemia, improve islet β-cell function and reduce the incidence of diabetic complications over a sustained period of time. Despite the fact that WJ-MSC infusion does not appear to attenuate insulin resistance, WJ-MSC infusion may have therapeutic potential as a novel agent for the treatment of T2DM.

Long term effect and safety of Wharton’s jelly-derived mesenchymal stem cells on type 2 diabetes’s_jelly-derived_mesenchymal_stem_cells_on_type_2_diabetes

  • Cellular therapies offer novel opportunities for the treatment of type 2 diabetes mellitus (T2DM). The present study evaluated the long-term efficacy and safety of infusion of Wharton’s jelly-derived mesenchymal stem cells (WJ-MSC) on T2DM. A total of 61 patients with T2DM were randomly divided into two groups on the basis of basal therapy; patients in group I were administered WJ-MSC intravenous infusion twice, with a four-week interval, and patients in group II were treated with normal saline as control. During the 36-month follow-up period, the occurrence of any adverse effects and the results of clinical and laboratory examinations were recorded and evaluated. The lack of acute or chronic adverse effects in group I was consistent with group II.. Blood glucose, glycosylated hemoglobin, C-peptide, homeostasis model assessment of pancreatic islet β-cell function and incidence of diabetic complications in group I were significantly improved, as compared with group II during the 36-month follow-up. The results of the present study demonstrated that infusion of WJ-MSC improved the function of islet β-cells and reduced the incidence of diabetic complications, although the precise mechanisms are yet to be elucidated. The infusion of WJ-MSC may be an effective option for the treatment of patients with type 2 diabetes.

Mesenchymal stem cells in tissue repair.

  • Mesenchymal stem cells have become a major focus for a potential resource in therapeutic cell-based therapies. MSCs are multipotent cells derived from stromal tissue, which have the capacity to differentiate into mesodermal and endodermal types of cells. Not only do MSCs have the capacity to differentiate into different types of cells depending on the tissue matrix, they also actively contribute to their milieu by secreting soluble products that actively participate in MSC and surrounding cell phenotype.

Mesenchymal stem cells from human umbilical cord express preferentially secreted factors related to neuroprotection, neurogenesis, and angiogenesis.

  • Our results confirmed that WJ-MSCs secreted highly levels of CXCL5 compared with BM-MSCs.

Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis.

  • In conclusion, human UC-MSCs suppressed the various inflammatory effects of FLSs and T cells of RA in vitro, and attenuated the development of CIA in vivo, strongly suggesting that UC-MSCs might be a therapeutic strategy in RA. In addition, the immunosuppressive activitiy of UC-MSCs could be prolonged by the participation of Tregs.

Stem cell delivery of therapies for brain disorders

  • MSCs have the potential as cellular vehicles for drugs and other molecules to treat patients with neural diseases such as GBM, AD, PD, TBI and other neuropathologies for which limited treatment options exist. When considering the limitations of current methods of drug delivery to the brain, MSCs have the potential to become a safe cellular delivery vehicle containing a prodrug as well as ectopically expressed genes for targeted delivery. The affinity for MSCs to migrate to the brain combined with the relative ease for expanded MSCs make them attractive for gene and drug delivery.
ReGenesis Medical Center
107 Aprill Dr., Suite 5
Ann Arbor, MI 48103
Phone: 734-234-8008
Fax: 734-212-6891
Office Hours

Get in touch